Nutritrace (Sodium Molybdate Dihydrate, Zinc Chloride, Chromic Chloride, Copper Chloride, Ferrous Chloride, Mang)

Sodium molybdate dihydrate supplies molybdenum, a cofactor for enzymes such as sulfite oxidase and xanthine oxidase. Together with the other trace elements, it facilitates oxidative metabolism, detoxification pathways, and the synthesis of nucleic acids, thereby maintaining normal cellular processes in patients on IV nutrition.

The dose of Nutritrace is individualized by the prescribing clinician based on the patient’s age, weight, clinical condition and laboratory trace‑element levels. Healthcare providers calculate the appropriate infusion volume and rate to meet the specific micronutrient requirements of each patient.

Safety data for Nutritrace in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Nutritrace, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and any required import documentation.

Nutritrace offers a comprehensive blend of six essential trace elements in a single injectable formulation, reducing the need for multiple separate infusions. Compared with products that contain only one or two elements, Nutritrace simplifies administration and helps maintain balanced micronutrient levels, though clinicians must still monitor individual element concentrations.

Nutritrace must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. Keep the vial in its original packaging until use and discard any solution that appears discolored or contains particles.

Nutritrace is administered intravenously, typically added to a compatible carrier solution and infused over a prescribed period. The exact infusion rate and dilution are determined by the prescriber, taking into account the patient’s overall fluid balance and concurrent IV therapies.

Serious risks include severe hypersensitivity reactions such as anaphylaxis, acute hepatic dysfunction, and toxic accumulation of copper or iron leading to organ damage. Prompt recognition of symptoms and immediate discontinuation of the infusion are essential to mitigate these risks.

Nutritrace should be avoided in patients with known hypersensitivity to any of its components, those with severe hepatic or renal impairment where trace‑element clearance is compromised, and individuals with disorders of metal metabolism such as Wilson’s disease or hemochromatosis, unless specifically directed by a specialist.